Similar articles

• Targeted therapies in lung cancer.

  Besse B, Ropert S, Soria JC. Besse B, et al. Ann Oncol. 2007 Jul;18 Suppl 9:ix135-42. doi: 10.1093/annonc/mdm308. Ann Oncol. 2007. PMID: 17631566 Review. No abstract available.
• Tyrosine kinase signal transduction inhibitors. Clinical trials.

  Scagliotti GV. Scagliotti GV. Suppl Tumori. 2002 Jul-Aug;1(4):S34-6. Suppl Tumori. 2002. PMID: 12415814 Review. No abstract available.
• Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly.

  Gridelli C, Massarelli E, Maione P, Rossi A, Herbst RS, Onn A, Ciardiello F. Gridelli C, et al. Cancer. 2004 Oct 15;101(8):1733-44. doi: 10.1002/cncr.20572. Cancer. 2004. PMID: 15386339 Review.
• [III. Role of Anti-Angiogenesis Therapy for Advanced Non-Small Cell Lung Cancer - Current Status and Future Challenges].

  Hirai F. Hirai F. Gan To Kagaku Ryoho. 2015 Aug;42(8):940-3. Gan To Kagaku Ryoho. 2015. PMID: 26353391 Japanese. No abstract available.
• Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC.

  Van Zandwijk N, Baas P. Van Zandwijk N, et al. Suppl Tumori. 2002 Jul-Aug;1(4):S37-8. Suppl Tumori. 2002. PMID: 12415815 Review. No abstract available.